---
title: "The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251739486.md"
description: "The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin dropping over 6%, and HYBIO, Cosunter, Haisen Pharm, TY PHAR., and others following suit"
datetime: "2025-08-06T01:52:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251739486.md)
  - [en](https://longbridge.com/en/news/251739486.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251739486.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/251739486.md) | [繁體中文](https://longbridge.com/zh-HK/news/251739486.md)


# The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%

The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%, and HYBIO, Cosunter, Haisen Pharm, and TY PHAR. also experiencing declines

### Related Stocks

- [Guilin Sanjin (002275.CN)](https://longbridge.com/en/quote/002275.CN.md)
- [HYBIO (300199.CN)](https://longbridge.com/en/quote/300199.CN.md)
- [Cosunter (300436.CN)](https://longbridge.com/en/quote/300436.CN.md)
- [Haisen Pharm (001367.CN)](https://longbridge.com/en/quote/001367.CN.md)
- [TY PHAR. (002728.CN)](https://longbridge.com/en/quote/002728.CN.md)

## Related News & Research

- [BREAKINGVIEWS-Donald Trump’s biggest trade shock is yet to come: podcast](https://longbridge.com/en/news/278498422.md)
- [Know a rising star in pharma marketing? Nominate them here](https://longbridge.com/en/news/278461777.md)
- [TECHNICALS-CBOT corn may stabilize around $4.68 and resume its climb](https://longbridge.com/en/news/278337583.md)
- [GRAINS-Grain prices gain as oil shoots higher on Middle East war](https://longbridge.com/en/news/278406774.md)
- [Republican US lawmaker doubles down after criticism of his anti-Muslim comments](https://longbridge.com/en/news/278618165.md)